Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026)
Exelixis (EXEL) recorded quarterly Depreciation & Amortization (CF) of $6.9 million in Q2 2026, little changed quarter-over-quarter from $6.9 million in Q1 2026, and down 5.41% on a YoY basis from $7.3 million in Q2 2025.
Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Exelixis' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $6.9 million for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 5.41% year-over-year to $6.9 million; the TTM figure through Apr 2026 stood at $28.7 million (down 3.74% YoY), while the FY2026 annual figure was $29.1 million, up 0.87% from the prior year.
- Depreciation & Amortization (CF) was $6.9 million for Q2 2026 at Exelixis, roughly flat from $6.9 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.6 million in Q1 2025 to a low of $4.5 million in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $6.6 million across 5 years, with a median of $6.9 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) jumped 207.92% in 2022, then declined 9.11% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $5.9 million in 2022, then increased by 9.75% to $6.5 million in 2023, then advanced by 14.22% to $7.5 million in 2024, then retreated by 0.43% to $7.4 million in 2025, then fell by 6.39% to $6.9 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $6.9 million (Q2 2026), $6.9 million (Q1 2026), and $7.4 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Exelixis | 13.72 Bn | 12.95 Bn | 590.86 Mn | 6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 6.95 Mn |
| Apr 3, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Dec 29, 2023 | 6.53 Mn |
| Dec 29, 2023 | 6.53 Mn |